Avero Diagnostics and VitaDX announce the signing of a strategic partnership for the distribution in the United States of VisioCyt® Bladder, a diagnostic test for bladder cancer

Avero Diagnostics and VitaDX announce the signing of a strategic partnership for the distribution in the United States of VisioCyt® Bladder, a diagnostic test for bladder cancer
Share this page

Bellingham (Washington, United States), Paris (France), December 18, 2023.

Avero Diagnostics, a renowned clinical laboratory specializing in oncological pathology, and VitaDX International, a deeptech company specializing in Artificial Intelligence and image processing for cancer detection, are delighted to announce the signing of a strategic partnership to deploy VisioCyt® Bladder throughout the United States.


With more than 800,000 patients affected, nearly 85,000 new cases and 17,000 deaths per year in the United States, bladder cancer represents a true public health challenge.

VisioCyt® Bladder is the only medical software capable of detecting bladder cancer from a simple urine sample. This CE IVDR-marked solution is currently available in Europe and addresses the needs of urologists, pathologists and their patients, who benefit from a non-invasive, sensitive, reproducible and rapid test that fits well into the patient's care pathway.


A strategic partnership for the international expansion of VitaDX and the broadening of Avero Diagnostics’ portfolio.

Joining forces with Avero Diagnostics, a national pathology laboratory, enables VitaDX to enter the several-hundred-million-dollar U.S. bladder cancer market and solidify its position as a key player in cancer diagnostics.

“Our mission is to provide reliable, non-invasive and accessible diagnostic solutions to as many patients as possible. This collaboration with Avero Diagnostics is a crucial step toward achieving that goal and supporting the development of VitaDX in the U.S. market”, said Allan Rodriguez, Managing Director of VitaDX International. “This partnership is the first step in making the VisioCyt® Bladder cancer test available to all patients suffering from bladder cancer in the United States.   It further strengthens Avero’s leadership position in oncology diagnostics and enables VitaDX to continue its ongoing commitment to improving patient care pathways.

“This partnership with VitaDX enhances Avero’s ability to offer innovative oncology diagnostic testing services by providing faster and more precise bladder cancer test results for healthcare providers and their patients, and we are fully invested in this collaboration”, said Dr. Ryan Fortna, President of Avero Diagnostics.

The VisioCyt® Bladder test will be available in the U.S. early in the first quarter of 2025.


About Avero Diagnostics Laboratories

Avero Diagnostics is a CLIA-certified and CAP-accredited cancer diagnostics laboratory dedicated to providing high-quality anatomic pathology, clinical pathology, molecular pathology and diagnostic services to physicians and their patients. Avero Diagnostics helps healthcare providers and organizations make informed decisions by providing sub-specialized pathology services in the fields of breast, dermatopathology, gynecology, hematopathology, gastrointestinal pathology, molecular pathology and urological pathology. Avero Diagnostics focuses on improving the delivery of healthcare to patients through the development and deployment of innovative diagnostic tests that deliver faster and more accurate results.


About VitaDX International

VitaDX - a French Deep Tech - designs and develops software solutions for cancer diagnosis, integrating image processing and artificial intelligence applied to cytology. AI - a disruptive innovation - is booming in the world of healthcare, and particularly in cancer diagnosis. With its first VisioCyt® Bladder solution, the company is able to diagnose bladder cancer from a simple urine sample, thus responding to the expectations of urologists and their patients for a sensitive and reproducible non-invasive test to monitor this disease; a little-publicized cancer that can be very aggressive and require regular monitoring, sometimes for life. The company's mission is to develop innovative, high-performance and reliable cancer diagnostic solutions, with a significant impact on medical and economic systems, for the benefit of as many patients as possible.

Document(s) joint(s)